Behind The Most Exciting Stock Pop In Years!

Target reported solid earnings this morning, which is a great sign for the consumer, but the big news today was from Moderna. The company’s clinical trial results for a cancer vaccine were so encouraging it was fast tracked through the trial and, while there are questions, this could change how we look at cancer in the future. We discuss why the stock is up over 100%. Plus, we end the show with the latest from OpenAI and Anthropic.

Travis Hoium, Lou Whiteman, and Rachel Warren discuss:

- Target Earnings
- Is Target Stock a Buy?
- Moderna’s HUGE News
- Scaling Qs
- Is AI Growth Slowing?
- Speed Running to an IPO

Companies discussed: Target (TGT), Moderna (MRNA), Merck (MRK).

Host: Travis Hoium
Guests: Lou Whiteman, Rachel Warren
Engineer: Kristi Waterworth

Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement.

We’re committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode.

Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices⁠

Learn more about your ad choices. Visit megaphone.fm/adchoices